L'intérêt à découvert pour Intelligent Bio Solutions donne aux investisseurs une idée du degré auquel les investisseurs parient sur la baisse de l'action de Intelligent Bio Solutions. Les données sur l'intérêt à découvert sont mises à jour toutes les deux semaines.

Intelligent Bio Solutions (NASDAQ:INBS) Stock, Rapport sur les intérêts à découvert

Intelligent Bio Solutions

Intelligent Bio Solutions Inc is a life sciences company developing non-invasive, real-time monitoring and diagnostic tests for patients and their primary health practitioners. Its Biosensor Platform is developing and launching diagnostic tests urgently needed to help people living with chronic diseases. It also engages in the advancement of portable drug abuse testing through the analysis of fingerprint sweat. The test is non-invasive, hygienic, and fast, and screens for recent use of opioids, cocaine, methamphetamines, benzodiazepines, and marijuana. The company business through two operating segments include Commercially available Intelligent Fingerprinting Products (IFPG or IFPG segment) and, Development Stage Biosensor Platform Technology (BPT segment).

Intelligent Bio Solutions Inc. - Common Stock

Intelligent Bio Solutions Inc

Big Rock Brewery (TSX:<a class="ticker" href="https://www.benzinga.com/stock/BR#TSX">BR</a>) reported $11.20 million in sales this quarter. This is a 30.51 percent increase over sales of $8.58 million the same period last year.

Earnings

News

TSX:BR

Big Rock Brewery Q1 Sales $11.20M Up From $8.58M YoY

Wells Fargo analyst Ike Boruchow maintains Academy Sports (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASO#NASDAQ">ASO</a>) with a Equal-Weight and raises the price target from $38 to $43.

Price Target

Analyst Ratings

Wells Fargo Maintains Equal-Weight on Academy Sports, Raises Price Target to $43

XRP (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/xrp/usd">XRP</a>) has surged 416% over the past year, with recent market data pointing to a strong undercurrent of accumulation despite heightened speculation. With institutional products rolling out and selling pressure being absorbed, analysts are eyeing a potential <a href="https://www.benzinga.com/money/ripple-xrp-price-prediction">bullish breakout on the horizon.</a>
<figure class="wp-block-table"> 
<table class="has-fixed-layout">
<tbody>
<tr>
<td>Cryptocurrency</td>
<td>Price&nbsp;&nbsp;&nbsp;</td>
<td>24-Hour Trend</td>
<td>7-Day Trend</td>
</tr>
<tr>
<td>XRP (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/xrp/usd">XRP</a>)</td>
<td>$2.58</td>
<td>+2%&nbsp;</td>
<td>+21.6%&nbsp;</td>
</tr>
<tr>
<td>Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>)</td>
<td>$104,021.57</td>
<td>+0.5%&nbsp;</td>
<td>+7.4%&nbsp;</td>
</tr>
<tr>
<td>Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>)</td>
<td>$2,614.78</td>
<td>+3.6%&nbsp;</td>
<td>+43.2%&nbsp;</td>
</tr>
</tbody>
</table>
</figure>
What Experts Are Saying: CryptoQuant analyst BorisVest <a href="https://x.com/cryptoquant_com/status/1922347861896794262">notes</a> that XRP appears to be gearing up for a bullish move. 
After a major flush that slashed open interest from an all-time high of $1.5 billion down to $530 million, the metric is now trending higher again, which is a sign of renewed speculative interest and rising volatility.
While the funding rate remains neutral, a deeper look reveals increasing short positions and a decline in funding, hinting at a possible short squeeze scenario developing. 
Additionally, the Taker Buy/Sell Ratio sits at 0.91, indicating strong selling pressure from retail traders.
However, the fact that price continues to hold firm suggests this pressure is being quietly absorbed, potentially signaling the early stages of a breakout. 
Statistics: According to Coinglass, XRP's open interest rose 2.7% in the past 24 hours to $5.66 billion, its highest level since early February. 
Liquidations during this period totaled $7.38 million, with $4.7 million in long positions and the rest in shorts, a sign of increasing leverage and volatility.
Community News: The CME Group has <a href="https://x.com/CMEGroup/status/1922313387989475332">confirmed</a> that XRP futures will launch on May 19, with both standard and micro contracts regulated by the CFTC. 
This development could attract institutional capital into XRP markets.
A commentator <a href="https://x.com/WKahneman/status/1922410636031451300">pointed</a> out that the Institute of International Finance (IIF) mentioned XRP via Ripple as a viable option for cross-border payments in its feedback to the Bank for International Settlements (BIS), a nod toward XRP's expanding role in global finance.
Read Next:&nbsp;
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/05/45387728/xrp-surges-21-in-7-days-how-high-can-it-go">XRP Surges 21% In 7 Days: How High Can It Go?</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

$ETH

$XRP

XRP Up 416% Over The Past Year: How High Can It Go?

Crescita Therapeutics (TSX:<a class="ticker" href="https://www.benzinga.com/stock/CTX#TSX">CTX</a>) reported quarterly losses of $(0.05) per share. This is a 66.67 percent decrease over losses of $(0.03) per share from the same period last year. The company reported $3.54 million in sales this quarter. This is a 29.20 percent decrease over sales of $5.00 million the same period last year.

TSX:CTX

Crescita Therapeutics Q1 EPS $(0.05) Down From $(0.03) YoY, Sales $3.54M Down From $5.00M YoY

B of A Securities analyst Curtis Nagle maintains Wayfair (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/W#NYSE">W</a>) with a Neutral and raises the price target from $36 to $43.

B of A Securities Maintains Neutral on Wayfair, Raises Price Target to $43

TerraVest Industries (TSX:<a class="ticker" href="https://www.benzinga.com/stock/TVK#TSX">TVK</a>) reported quarterly earnings of $1.39 per share which beat the analyst consensus estimate of $0.81 by 71.6 percent. This is a 16.81 percent increase over earnings of $1.19 per share from the same period last year. The company reported quarterly sales of $311.45 million which beat the analyst consensus estimate of $300.63 million by 3.60 percent. This is a 44.90 percent increase over sales of $214.94 million the same period last year.

Earnings Beats

TSX:TVK

TerraVest Industries Q2 EPS $1.39 Beats $0.81 Estimate, Sales $311.45M Beat $300.63M Estimate

B of A Securities analyst Curtis Nagle maintains RH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RH#NYSE">RH</a>) with a Underperform and raises the price target from $144 to $172.

B of A Securities Maintains Underperform on RH, Raises Price Target to $172

Firefly Neuroscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIFF#NASDAQ">AIFF</a>) reported quarterly losses of $(1.74) per share. This is a 690.91 percent decrease over losses of $(0.22) per share from the same period last year. The company reported $43.00 thousand in sales this quarter. This is a 258.33 percent increase over sales of $12.00 thousand the same period last year.

AIFF

Firefly Neuroscience Q1 EPS $(1.74) Down From $(0.22) YoY, Sales $43.00K Up From $12.00K YoY

Toray Industries (OTC:<a class="ticker" href="https://www.benzinga.com/stock/TRYIY#OTC">TRYIY</a>) reported quarterly earnings of $0.03 per share. This is a 112.5 percent increase over losses of $(0.20) per share from the same period last year. The company reported $4.19 billion in sales this quarter. This is a 2.08 percent decrease over sales of $4.28 billion the same period last year.

TRYIY

Toray Industries Q4 EPS $0.03 Up From $(0.20) YoY, Sales $4.19B Down From $4.28B YoY

Sysmex (OTC:<a class="ticker" href="https://www.benzinga.com/stock/SSMXY#OTC">SSMXY</a>) reported quarterly earnings of $0.06 per share. This is a 120 percent increase over losses of $(0.29) per share from the same period last year. The company reported $929.63 million in sales this quarter. This is a 2.20 percent increase over sales of $909.66 million the same period last year.

SSMXY

Sysmex Q4 EPS $0.06 Up From $(0.29) YoY, Sales $929.63M Up From $909.66M YoY

Charlottes Web Holdings (TSX:<a class="ticker" href="https://www.benzinga.com/stock/CWEB#TSX">CWEB</a>) reported quarterly losses of $(0.04) per share. This is a 33.33 percent increase over losses of $(0.06) per share from the same period last year. The company reported $12.26 million in sales this quarter. This is a 1.14 percent increase over sales of $12.12 million the same period last year.

TSX:CWEB

Charlottes Web Holdings Q1 EPS $(0.04) Up From $(0.06) YoY, Sales $12.26M Up From $12.12M YoY

Benchmark analyst Bill Sutherland maintains Quipt Home Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QIPT#NASDAQ">QIPT</a>) with a Buy and lowers the price target from $6 to $4.

QIPT

Benchmark Maintains Buy on Quipt Home Medical, Lowers Price Target to $4

B of A Securities analyst Vivek Arya maintains Advanced Micro Devices (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>) with a Buy and raises the price target from $120 to $130.

B of A Securities Maintains Buy on Advanced Micro Devices, Raises Price Target to $130

Carlos "Los" Arias spent years building one of California's most ambitious cannabis companies. But the moment that mattered most didn't happen under grow lights or in a boardroom.
It happened at Cedars-Sinai Hospital, where Arias, then deep in Colorado's cannabis industry, begged a doctor to recommend medical cannabis to his skeptical Cuban-American father, Manuel F. Arias.
"I saw cannabis as a drug, and my son was telling me he wanted to be a drug dealer," Manuel would later recall. "How could I be happy about that?"
What followed changed both of their lives and laid the groundwork for a new legacy.
<h3 class="wp-block-heading">From Misunderstanding To Reconciliation</h3>
In 2012, Manuel was preparing to hand over the family's health insurance brokerage to his son Los, who, fresh out of law school, had other plans. He wanted to get into the cannabis industry—an idea his father couldn't support.
Then came Manuel's stroke in 2014.
During recovery, Manuel's physician at Cedars-Sinai turned out to be a medical cannabis advocate. On his son's urging, Manuel began taking edibles and tinctures. Sleep improved. Healing accelerated. And slowly, something else happened: the wall between father and son began to fall.
"Cannabis helped save my life," Manuel says now. "I realized Los was right all along."
<h3 class="wp-block-heading">Building Green Horizons—And New Ones</h3>
By 2015, Los was co-owner of RiverRock, one of Colorado's first licensed cannabis businesses. After exiting that company, he returned to California and, in 2017, secured one of the state's first cultivation licenses under Proposition 64. A year later, he co-founded Green Horizons, a large-scale cannabis facility in Coachella.
Today, the company operates a 101,787 sq. ft. Phase I facility and is preparing to break ground on Phase II, pushing toward a planned one million sq. ft. campus. The company has drawn high-profile attention, including a partnership with Tommy Hilfiger.
But Los still felt something was missing.
<h3 class="wp-block-heading">The Birth Of Flostar Group</h3>
Quietly, Los reached out to Amarilys Serrano, a longtime associate of his father's in the insurance business. Together, they launched Flostar Group, a new brokerage serving both cannabis and non-cannabis clients, with a twist: Los made sure the website named Manuel as the founder.
"He is the founder. He started it," said Los. "I'm just closing the circle some years later and proving that love doesn't have a timeline. He's my hero."
Flostar now services companies across industries, including Green Horizons. Serrano's three decades of experience, paired with Los' network, helped secure millions of dollars in premiums in the brokerage's early days. While cannabis is part of the client base, most Flostar clients operate in other industries.
"Taking care of people's health and providing great insurance at affordable prices is relevant for all companies," said Los.
Manuel, now 84, serves as chairman emeritus and still helps with accounting. "I've paid a lot of bills over the years, and it keeps my mind sharp," he said. "And then I get to eat an edible to relax. It's never too late to turn over a new leaf."
<h3 class="wp-block-heading">Speaking At Benzinga's Cannabis Capital Conference</h3>
Carlos "Los" Arias will be speaking at the <a href="https://www.benzinga.com/cannabis-conference">Benzinga Cannabis Capital Conference</a>, returning to Chicago from June 8–10.
He'll join a high-powered panel titled: &#8220;Can the Sun Compete with the Socket? Greenhouse vs Indoor in the Fight for Premium Pricing.&#8221;
As indoor-grown cannabis continues to dominate premium pricing, the panel will explore whether rising energy costs and next-gen greenhouse technology can shift the model.
Panelists include:
<ul class="wp-block-list">
<li>Los Arias, CEO, Green Horizons</li>
<li>Darren Lampert, CEO, GrowGeneration</li>
<li>Michael Meade, Green Horizons</li>
<li>Michael Salaman, President, GrowGeneration</li>
<li>Moderator: Rachelle Gordon, GreenState</li>
</ul>
Tickets are on sale now. Visit the <a href="https://www.benzinga.com/cannabis-conference">Benzinga Cannabis Capital Conference</a> website to join the conversation and meet top executives shaping the future of cannabis.
Image courtesy of Los Arias.

Cannabis

Events

'I Thought He Wanted To Be A Drug Dealer,' How Cannabis Healed A Father-Son Rift And Sparked Two Thriving Businesses

Mowi (OTC:<a class="ticker" href="https://www.benzinga.com/stock/MHGVY#OTC">MHGVY</a>) reported quarterly earnings of $0.30 per share. This is a 30.43 percent increase over earnings of $0.23 per share from the same period last year. The company reported $1.43 billion in sales this quarter. This is a 1.45 percent decrease over sales of $1.45 billion the same period last year.

MHGVY

Mowi Q1 Adj. EPS $0.30 Up From $0.23 YoY, Sales $1.43B Down From $1.45B YoY

Scotiabank analyst Phil Hardie maintains Power Corp of Canada (TSX:<a class="ticker" href="https://www.benzinga.com/stock/POW#TSX">POW</a>) with a Sector Outperform and lowers the price target from C$61 to C$57.

TSX:POW

Scotiabank Maintains Sector Outperform on Power Corp of Canada, Lowers Price Target to C$57

Rakuten Group (OTC:<a class="ticker" href="https://www.benzinga.com/stock/RKUNY#OTC">RKUNY</a>) reported quarterly losses of $(0.22) per share. This is a 69.23 percent decrease over losses of $(0.13) per share from the same period last year. The company reported $3.69 billion in sales this quarter. This is a 6.62 percent increase over sales of $3.46 billion the same period last year.

RKUNY

Rakuten Group Q1 EPS $(0.22) Down From $(0.13) YoY, Sales $3.69B Up From $3.46B YoY

WELL Health Technologies (TSX:<a class="ticker" href="https://www.benzinga.com/stock/WELL#TSX">WELL</a>) reported quarterly earnings of $0.03 per share which missed the analyst consensus estimate of $0.07 by 57.14 percent. This is a 62.5 percent decrease over earnings of $0.08 per share from the same period last year. The company reported quarterly sales of $294.14 million which beat the analyst consensus estimate of $276.35 million by 6.44 percent. This is a 27.02 percent increase over sales of $231.56 million the same period last year.

Earnings Misses

TSX:WELL

WELL Health Technologies Q1 Adj. EPS $0.03 Misses $0.07 Estimate, Sales $294.14M Beat $276.35M Estimate

Benchmark analyst Bruce Jackson maintains Humacyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HUMA#NASDAQ">HUMA</a>) with a Buy and lowers the price target from $17 to $14.

HUMA

Benchmark Maintains Buy on Humacyte, Lowers Price Target to $14

B of A Securities analyst Vivek Arya maintains NVIDIA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) with a Buy and raises the price target from $150 to $160.

Comments

Intelligent Bio Solutions

Intérêt court

Intelligent Bio Solutions (NASDAQ:INBS) Stock, Rapport sur les intérêts à découvert

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL